Worldwide, more than one million people die each year from hepatitis C virus (HCV) related
diseases, and over 300 million people are chronically infected with hepatitis B or C. Egypt …

An estimated 8–10 million people suffer from viral hepatitis in Egypt. Hepatitis A virus (HAV)
and hepatitis E virus (HEV) are the major causes of viral hepatitis in Egypt as 50% or more of …

Background Treatment of chronic hepatitis C using combination of sofosbuvir (SOF) and
daclatasvir (DCV) was used in several clinical trials and multicentre studies, which were …

Novel direct‐acting antivirals (DAA s) are now the standard of care for the management of
hepatitis C virus (HCV) infection. Branded DAA s are associated with high sustained …

Chronic infection with the hepatitis C virus (HCV) remains a major health problem affecting
approximately 58 million people worldwide. In the era of interferon (IFN)-based regimens …

Background and Aims The introduction of direct-acting antivirals for hepatitis C virus (HCV)
in Egypt led to massive treatment uptake, with Egypt's national HCV treatment program …

Objective We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with
ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were …

Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable Page 1 254 |CliniCal
liver Disease, vOl 16, nO 6, DeCeMBer 2020 An Official Learning Resource of AASLD review …

Background & Aims The prevalence of anti-hepatitis C virus antibody in Punjab, India is
3.6%, with 728,000 people estimated to have viremic chronic hepatitis C (CHC). The Mukh …

Introduction: Currently, direct-acting antivirals (DAAs) are considered the ideal choice for the
treatment of chronic HCV patients due to their proven efficacy (SVR> 90%), and minimal …